Physician profile
Michael Everett Buschur
NPI 1851418107
$45,547.61
in general payments reported to CMS, 2019-2025
18 companies · $37K in 2025
The $37K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,636 · 2020: $2,515 · 2021: $233 · 2022: $243 · 2023: $722 · 2024: $1,122 · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Travel and Lodging: $14K · Consulting Fee: $4,125 · Food and Beverage: $3,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,125.00 |
| Travel and Lodging | $13,706.07 |
| Consulting Fee | $4,125.00 |
| Food and Beverage | $3,964.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $35,534.87 | 2021-2025 | Symplicity G3, Onyx Frontier, Ffrangio |
| Edwards Lifesciences Corporation | $4,213.35 | 2020-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Ekos Corporation | $3,501.99 | 2019 | |
| Penumbra, INC. | $1,108.08 | 2025 | Indigo System, Ruby Coil |
| Novartis Pharmaceuticals Corporation | $261.02 | 2021-2025 | |
| Abbott Laboratories | $253.66 | 2019-2025 | Amplatzer Amulet, Pressurewire, Portico |
| Medtronic Vascular, INC. | $109.78 | 2019 | |
| Pfizer INC. | $98.45 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.76 | 2020-2025 | Lifevest |
| Amgen INC. | $83.56 | 2022-2023 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $80.43 | 2022-2023 | Brilinta, Farxiga |
| Cardiva Medical, INC. | $59.40 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Merck Sharp & Dohme LLC | $40.32 | 2023 | Verquvo |
| Abiomed | $35.86 | 2025 | |
| Janssen Pharmaceuticals, INC | $30.76 | 2023 | Xarelto |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $23.45 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.87 | 2025 | Camzyos |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Buschur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.